# ClinicalIntelPulse Global Trial Landscape

> ClinicalIntelPulse Global Trial Landscape is a paid API for AI agents from clinicalintelpulse.vercel.app, paid per call via x402, $0.15/call, status unknown (last checked 2026-09-15).

Returns international clinical trial geographic distribution across WHO ICTRP registries (US, EU, China, India, Japan, Brazil and more), highlighting access gaps and unmet need for any disease area

## Facts

- Endpoint: GET https://clinicalintelpulse.vercel.app/api/clinical/global-trials
- Price: $0.15/call
- Payment: x402
- Status: unknown
- Last checked: 2026-09-15
- Activations on Zero: 0
- Tags: x402
- Canonical page: https://www.zero.xyz/c/clinicalintelpulse-global-trial-landscape-16a0c199
- Structured record (JSON): https://api.zero.xyz/v1/capabilities/cap_tXOvE-7Jn2oWQWGEH-QOb

Status and success rate cover calls made through Zero and Zero's own probes. Third-party monitors may report differently.

## How to call it through Zero

Zero handles the 402 payment challenge and records the run. With the Zero CLI installed (`npm i -g @zeroxyz/cli`):

```sh
zero fetch --capability clinicalintelpulse-global-trial-landscape-16a0c199
```

Example prompt: Give me the international trial landscape for type 2 diabetes — I want to see how trials are distributed across WHO ICTRP registries like the US, EU, China, India, and Japan, and where the biggest access gaps or unmet needs are.

## When to prefer this

Choose this endpoint when you need a geopolitical and geographic view of the clinical trial landscape for a disease — specifically WHO ICTRP multi-registry coverage spanning US, EU, China, India, Japan, Brazil and beyond. Prefer this over general pipeline endpoints when the goal is site feasibility, access equity analysis, international expansion strategy, or advocacy gap identification rather than phase/sponsor/mechanism breakdowns.

## Known failure modes

- Unknown or misspelled disease name returns empty results or error
- Disease area too broad may return aggregate data with limited granularity
- Registry data lag may mean very recently opened trials are not yet reflected
- Rare diseases with few global trials may return sparse geographic data
- Network timeout for diseases with very large trial volumes

## How this service works

Global clinical trial landscape for any disease — geographic distribution by country across WHO ICTRP registries (US, EU, China, India, Japan, Brazil, Africa and more), regulatory pathways, access gaps and unmet need by region. For CRO, global-pharma and advocacy agents.

## Output

A structured breakdown of active clinical trials for the queried disease across major WHO ICTRP registries, including trial counts by country/region, geographic distribution patterns, identification of access gaps (regions with few or no trials), and unmet need signals — useful for CRO site selection, global pharma strategy, and patient advocacy planning.

## Request schema (JSON Schema)

```json
{
 "type": "object",
 "$schema": "https://json-schema.org/draft/2020-12/schema",
 "required": [
  "input"
 ],
 "properties": {
  "input": {
   "type": "object",
   "required": [
    "type",
    "method"
   ],
   "properties": {
    "type": {
     "type": "string",
     "const": "http"
    },
    "method": {
     "enum": [
      "GET",
      "HEAD",
      "DELETE"
     ],
     "type": "string"
    },
    "queryParams": {
     "type": "object",
     "properties": {
      "lang": {
       "type": "string"
      },
      "region": {
       "type": "string"
      },
      "condition": {
       "type": "string"
      }
     }
    }
   },
   "additionalProperties": false
  },
  "output": {
   "type": "object",
   "required": [
    "type"
   ],
   "properties": {
    "type": {
     "type": "string"
    },
    "errors": {
     "type": "object",
     "description": "Documented error responses, keyed by HTTP status code",
     "additionalProperties": {
      "type": "object",
      "required": [
       "description"
      ],
      "properties": {
       "example": {
        "type": "object"
       },
       "description": {
        "type": "string"
       }
      }
     }
    },
    "example": {
     "type": "object"
    }
   }
  }
 }
}
```

## Response schema (JSON Schema)

```json
{
 "type": "json",
 "example": {
  "query_summary": {
   "region": "global",
   "condition": "Malaria"
  },
  "phase3_highlights": [
   {
    "drug": "R21/Matrix-M",
    "notes": "WHO prequalification received 2023. First malaria vaccine with >75% efficacy in high-transmission settings.",
    "sponsor": "Serum Institute / Oxford",
    "countries": [
     "Burkina Faso",
     "Kenya",
     "Mali",
     "Tanzania"
    ]
   }
  ],
  "regulatory_landscape": {
   "ema": "Article 58 mechanism for non-EU disease burden assessments. R21 assessed via UK MHRA.",
   "fda": "Limited footprint — malaria not a US priority market; few NDA filings",
   "nmpa_china": "Artemisinin derivatives approved; combination therapies standardized under WHO guidelines",
   "who_prequalification": "Primary pathway for SSA deployment. RTS,S and R21 both WHO-prequalified."
  },
  "unmet_needs_by_region": {
   "latin_america": "Vivax malaria (neglected vs. falciparum)",
   "southeast_asia": "Artemisinin resistance (Pfkrelch mutations) — urgent — treatment of resistant falciparum",
   "sub_saharan_africa": "Pediatric dosing, pregnancy, severe malaria, transmission blocking"
  },
  "opportunity_assessment": "R21 scale-up is the near-term priority. Resistance crisis in SE Asia creates urgent Phase 3 need for alternative regimens.",
  "global_trial_distribution": {
   "most_active_countries": [
    "Kenya (45 trials)",
    "Uganda (38)",
    "Burkina Faso (31)",
    "Mali (28)",
    "Tanzania (24)",
    "United States (22)",
    "Thailand (19)"
   ],
   "clinicaltrials_gov_count": 312,
   "geographic_concentration": "Sub-Saharan Africa dominates — 68% of all active malaria trials",
   "estimated_non_us_registries": "200+ additional trials in WHO ICTRP member registries"
  },
  "global_registries_coverage": {
   "ctri_india": "18 trials — India significant manufacturer (Serum Institute)",
   "chictr_china": "Limited malaria — primarily domestic infectious disease",
   "anzctr_australia": "5 trials — malaria research centers in Melbourne (Burnet Institute)",
   "clinical_trials_eu": "12 EU-registered trials"
  },
  "development_finance_context": "GAVI, Global Fund, UNITAID, PMI, USAID funding dominant. Wellcome Trust largest private funder."
 }
}
```

## More

- Live health (JSON, refreshed every minute): https://www.zero.xyz/c/clinicalintelpulse-global-trial-landscape-16a0c199/health.json
- [Zero catalog index](https://www.zero.xyz/llms.txt)
- [Other services from clinicalintelpulse.vercel.app](https://www.zero.xyz/host/clinicalintelpulse.vercel.app/llms.txt)